ARTICLE | Deals
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger
Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ
November 8, 2024 10:36 PM UTC
A reverse merger will bring Samsara-backed Kalaris onto NASDAQ as it advances a long-acting VEGF inhibitor through the clinic that may have advantages over marketed therapies.
Kalaris Therapeutics Inc. is merging with AlloVir Inc. (NASDAQ:ALVR) several months after that company discontinued development of an antiviral T cell therapy that had reached Phase III testing...